Indefinite Delivery Contract HHSN261201200019I
Award Date
9/20/12
Last Date to Order
9/19/14
Federal Agency
National Cancer Institute
Awardee
IIT Research Institute
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract (IDC) was awarded by a U.S. federal government agency to IIT Research Institute (IITRI), a non-profit contract research organization. The IDC is a multiple-award vehicle with a $0 ceiling value and an ultimate completion date of September 30, 2007. Under this IDC, IITRI provides a range of preclinical research services to support federal agencies such as the National Institutes of Health (NIH), including the National Cancer Institute (NCI), National Institute of...
This indefinite delivery contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to the IIT Research Institute (IITRI), a subsidiary of the Illinois Institute of Technology. The contract has a ceiling value of $146.3 million and a period of performance through July 2031. The purpose of this IDC is to provide NIAID with a range of preclinical research services related to the development and...
This indefinite delivery contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health within the Department of Health and Human Services, to IIT Research Institute (IITRI), a non-profit contract research organization. The $74,995,000 multiple-award contract, titled the "PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarkers," supports preclinical efficacy and biomarker evaluation, manufacturing, and...
The key products and services being delivered under this federal contract IDV award from the National Cancer Institute (NCI) are preclinical toxicology studies on small molecule drug candidates for cancer and other indications. The prime contractor, IIT Research Institute (IITRI), a division of the Illinois Institute of Technology, will conduct non-GLP and GLP toxicology assessments in mice and dogs to support Investigational New Drug (IND) applications. IITRI holds several significant IDIQ...
This federal indefinite delivery contract was awarded by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to the non-profit IIT Research Institute (IITRI). The $19 million PREVENT Toxicology and Pharmacology Testing (PREVENT TOX) IDIQ contract vehicle enables NCI to efficiently access IITRI's preclinical research capabilities on an as-needed basis to support the development of cancer prevention therapies. Task orders issued under this...
This federal Indefinite Delivery Contract (IDC) was awarded by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to Mriglobal, doing business as Midwest Research Institute, a 501(c)(3) not-for-profit research organization. The $49,990,000 single-award IDC has an ultimate completion date of June 30, 2028 and does not have a set-aside designation. Under this IDC, Mriglobal is providing a range of scientific research, testing, and product...
The Indefinite Delivery Contract (IDC) with ID 75N91024D00006 was awarded by the National Cancer Institute (NCI), a civilian agency, to the Weill Medical College of Cornell University. This multiple-award IDC, with a ceiling value of $149,995,000, supports the PREVENT Cancer Preclinical Drug Development Program through the provision of preclinical research services. The IDC's scope includes evaluating the efficacy of potential cancer preventive agents, identifying relevant biomarkers, developing...
This is a multiple award indefinite delivery contract awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to conduct safety evaluation and toxicology studies to support drug development. The $48.6 million contract has a 6-year ordering period from June 2024 to June 2030. The contractor, IIT Research Institute (IITRI), a non-profit research organization, will perform in vitro and in vivo exploratory and...
This Indefinite Delivery Contract (IDC) was awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the Department of Health and Human Services, to the prime contractor Southern Research Institute, a non-profit research organization located in Birmingham, Alabama. The IDC, with a ceiling value of $17,891,012, is to provide CRO (Contract Research Organization) support for NCATS' Medicinal Chemistry for Lead Optimization program. This includes services...
The National Cancer Institute (NCI) awarded a $74,995,000 multiple-award indefinite delivery/indefinite quantity (IDIQ) contract called the PREVENT Preclinical Drug Development Program to support preclinical pharmacology, toxicology, and product development services for cancer therapy candidates. The prime contractor, IIT Research Institute (IITRI), is a non-profit division of the Illinois Institute of Technology that specializes in these preclinical services for federal agencies. Under this...